Guardant Health, Inc. (GH) stock

GHNasdaqServices-Medical LaboratoriesFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 10/30

$151.70−3.16 (-2.04%)

Close on Nov 13, 2026Market cap $20.36BP/E –Yield –

Guardant Health price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Guardant Health's price to sales ratio was 17.5× on Nov 11, 2026, against 15.0× a year earlier. Over the last 5 years it ranged from 3.9× to 29.6×, with a median of 8.4×.

Price to Sales Ratio at the end of each year

Period	Period end	Value	Change (pts)
2026	Nov 11, 2026	17.5×	+3.3
2025	Dec 31, 2025	14.1×	+8.7
2024	Dec 31, 2024	5.4×	−0.5
2023	Dec 29, 2023	5.9×	−0.5
2022	Dec 30, 2022	6.5×	−23.1
2021	Dec 31, 2021	29.6×	−17.9
2020	Dec 31, 2020	47.5×	+7.7
2019	Dec 31, 2019	39.8×	+33.5
2018	Dec 31, 2018	6.3×	–

Where these numbers come from

Parsed from the XBRL in Guardant Health's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing